Quanterix Corporation - QTRX STOCK NEWS

Quanterix Corporation (NASDAQ: QTRX) announced a leadership transition effective April 25, 2022. Masoud Toloue will take over as CEO, succeeding Kevin Hrusovsky, who becomes Executive Chairman. This shift aims to enhance Quanterix's growth potential in precision health. Under Hrusovsky's tenure, the company achieved over $100 million in revenues and raised $700 million in capital. Future strategies include ongoing collaborations with major companies like Eli Lilly and Abbott to drive innovation.

Quanterix Corporation (NASDAQ: QTRX) reported a strong financial performance for the fourth quarter and full year of 2021, achieving a 28% increase in GAAP total revenue, reaching $110.6 million. Notable highlights include a 49% rise in product revenue for Q4, totaling $23.5 million. The company ended the year with approximately $399 million in cash. Key advancements included FDA Breakthrough Device Designation for the pTau-181 blood test for Alzheimer’s disease and successful collaboration agreements with Eli Lilly. A leadership transition is set for April 2022, with Masoud Toloue becoming CEO.

Quanterix Corporation (NASDAQ: QTRX) has received multiple awards in the 2021 Best Places to Work Awards by Comparably, highlighting its commitment to a diverse and inclusive workplace. The company was recognized in five categories: Best Company for Diversity, Best Company for Women, Best Company Culture, Best Company Happiness, and Best Company Compensation. The awards were based on over 1,000 employee ratings. CEO Kevin Hrusovsky emphasized the importance of fostering an environment where all employees feel valued and empowered.

Quanterix Corporation (NASDAQ: QTRX) announced it will release its fourth quarter 2021 financial results on March 1, 2022, prior to market opening. A conference call hosted by CEO Kevin Hrusovsky will take place at 8:30 a.m. EST to discuss the results and provide a business update. Interested parties can participate via phone or listen to a live webcast. Quanterix focuses on digitizing biomarker analysis to enhance precision health, aiming for early disease detection and improved treatments.

Quanterix Corporation (NASDAQ: QTRX) announced that its Chairman and CEO, Kevin Hrusovsky, will present virtually at the SVB Leerink Global Healthcare Conference on February 16 at 4:20 PM EST. A live webcast will be accessible via the company's investor relations website, with on-demand replays available for 90 days post-conference. Hrusovsky will also hold virtual one-on-one meetings with institutional investors on February 18. Quanterix focuses on digitizing biomarker analysis to enhance precision health, with applications in oncology, neurology, and more.

Quanterix Corporation (NASDAQ: QTRX) announced its Simoa® technology is advancing neurodegenerative disease research at the UK Dementia Research Institute's Biomarker Factory. Led by Professor Henrik Zetterberg, this initiative aims to enhance early detection of Alzheimer’s and related diseases through ultrasensitive biomarker testing. The UK DRI is collaborating with Quanterix to develop next-generation Simoa technology, which offers a potential 100x improvement in sensitivity. This progress may lead to earlier diagnosis and more effective treatment options for Alzheimer’s.

Quanterix Corporation (NASDAQ: QTRX) announced that its Simoa® technology has played a significant role in a study published in Science, revealing a strong link between the Epstein-Barr virus (EBV) and multiple sclerosis (MS). The study indicates that EBV infection increases MS risk by 32-fold and correlates with elevated levels of neurofilament light (NfL) protein, suggesting EBV's involvement in nerve damage. This research could enhance early detection and treatment of MS, affecting millions globally.

Quanterix Corporation (NASDAQ: QTRX) reported expected Q4 2021 revenue between $29-31 million and full-year revenue between $109-111 million. Noteworthy Q4 growth includes product and service revenue expected at $28-30 million, representing 35% growth year-over-year. For the full year, product revenue is projected at $80-82 million, an 84% increase. The company is advancing precision health with its biomarker detection technology, receiving FDA Breakthrough Device Designation for its Alzheimer’s test.

Quanterix Corporation (NASDAQ: QTRX) announced that its Chairman and CEO, Kevin Hrusovsky, will present at the 40th Annual J.P. Morgan Healthcare Conference on Thursday, January 13, 2022, at 8:15 a.m. EST. This marks Hrusovsky's sixth consecutive year presenting at the conference, where he will discuss the company's growth and vision. Additionally, he will host one-on-one meetings with institutional investors. Investors can access the live webcast of the presentation at Quanterix's conference webpage. The company's technology aims to enhance precision health through advanced biomarker analysis.